MiyawakiKYamadaYBanNIharaYTsukiyamaKZhouHet al
Weight loss accounts for the remaining benefit, meaning patients experience meaningful blood pressure improvement even if their initial weight loss plateaus, though maximum benefit typically emerges after 8-12 weeks of consistent therapy
In clinical trials, nausea (12-22%), diarrhea (12-16%), vomiting (5-9%), constipation (6-7%), abdominal pain (6-9%), and dyspepsia (7-10%) were frequently reported
Found is not affiliated with or endorsed by Novo Nordisk, the manufacturer of Wegovy, Ozempic, Saxenda, and other GLP-1 medications
Kokkorakis M, Chakhtoura M, Rhayem C et al (2025) Emerging pharmacotherapies for obesity: a systematic review